BIOCRYST PHARMACEUTICALS INC - FORM 10-K - EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - March 6, 2012

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - BIOCRYST PHARMACEUTICALS INCFinancial_Report.xls
10-K - FORM 10-K - BIOCRYST PHARMACEUTICALS INCd306545d10k.htm
EX-21 - SUBSIDIARIES OF THE REGISTRANT - BIOCRYST PHARMACEUTICALS INCd306545dex21.htm
EX-23 - CONSENT OF ERNST & YOUNG, LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - BIOCRYST PHARMACEUTICALS INCd306545dex23.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - BIOCRYST PHARMACEUTICALS INCd306545dex312.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - BIOCRYST PHARMACEUTICALS INCd306545dex311.htm
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - BIOCRYST PHARMACEUTICALS INCd306545dex322.htm
EX-10.32 - AMENDED AND RESTATED DEVELOPEMENT AND LICENSE AGREEMENT - BIOCRYST PHARMACEUTICALS INCd306545dex1032.htm
EX-10.36 - FIFTH AMENDMENT AGREEMENT - BIOCRYST PHARMACEUTICALS INCd306545dex1036.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of BioCryst Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/    Jon P. Stonehouse
Jon P. Stonehouse
Chief Executive Officer

March 6, 2012

This certification is furnished with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

BIOCRYST PHARMACEUTICALS INC Reports